அலெக்சியன் ஏற்பாடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stealth BioTherapeutics Reports Fiscal Year 2020 Financial Results And Recent Business Highlights
Phase 2b dry AMD patient recruitment completed with topline data expected Q2 2022
NDA submission for elamipretide for cardiomyopathy in Barth syndrome may be delayed based on recent FDA feedback and ongoing interactions
Clinical expansion efforts underway for elamipretide in rare metabolic cardiomyopathies and in rare mitochondrial disease caused by nuclear DNA mutations
Pipeline development ongoing with SBT-272, SBT-550, and other pipeline compounds
Management to host conference call today at 8:30am ET
News provided by
Share this article
Share this article
BOSTON, April 6, 2021 /PRNewswire/  Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the year ....

United States , Reenie Mccarthy , Janhavi Mohite , Company Phase , Company Adss , Division Of Cardiology , Morningside Venturei Investments Ltd , Exchange Commission , Development Rd Expenses , Development Funding Agreement , Barth Syndrome Foundation , Stealth Biotherapeutics Corp Nasdaq , Stealth Biotherapeutics Inc , Chief Executive Officer , New Drug Application , Demonstrating Substantial Evidence , Amyotrophic Lateral Sclerosis , Frontotemporal Lobar Degeneration , Lewy Body Dementia , Progressive Supranuclear Palsy , Morningside Venture , Investments Ltd , Alexion Arrangement , Primary Mitochondrial Myopathy , Private Securities Litigation Reform Act , Annual Report ,